Oncternal Therapeutics (NASDAQ:ONCT) Earns Hold Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) in a report issued on Friday. The firm issued a hold rating on the stock.

Oncternal Therapeutics Stock Performance

NASDAQ:ONCT opened at $0.53 on Friday. Oncternal Therapeutics has a 1 year low of $0.53 and a 1 year high of $13.14. The stock has a market cap of $1.56 million, a P/E ratio of -0.05 and a beta of 1.18. The stock has a 50-day simple moving average of $0.53 and a 200-day simple moving average of $2.04.

Oncternal Therapeutics Company Profile

Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.